PT - JOURNAL ARTICLE AU - Kastaun, Sabrina AU - Garnett, Claire AU - Wilm, Stefan AU - Kotz, Daniel TI - Prevalence and characteristics of hazardous and harmful drinkers receiving general practitioners’ brief advice on and support with alcohol consumption in Germany: results of a population survey AID - 10.1101/2022.04.25.22274258 DP - 2022 Jan 01 TA - medRxiv PG - 2022.04.25.22274258 4099 - http://medrxiv.org/content/early/2022/04/26/2022.04.25.22274258.short 4100 - http://medrxiv.org/content/early/2022/04/26/2022.04.25.22274258.full AB - Objective The German treatment guideline on alcohol-related disorders recommends that general practitioners (GPs) offer brief advice on, and support with, reducing alcohol consumption to hazardous (at risk for health events) and harmful (exhibit health events) drinking patients. We aimed to estimate the implementation of this recommendation using data from the general population in Germany.Design Cross-sectional analysis of data (2021/2022) of a nationally representative household survey.Setting Population of Germany.Participants Representative sample of 2,247 adult respondents (>18 years) who reported hazardous or harmful drinking according to the Alcohol Use Disorders Identification Test-Consumption (AUDIT-C; score females: 4-12, males: 5-12).Main outcome measure Ever receipt of “brief GP advice on, or support with, reducing alcohol consumption”. Differences in the likelihood of ever receiving advice and/or support (yes/no) relative to respondents’ sociodemographic, smoking, and alcohol consumption characteristics were estimated using logistic regressions.Results Ever receipt of GP advice on/support with reducing alcohol was reported among 6.3% (95%CI=5.3%-7.4%), and the offer of support among 1.5% (95%CI=1.1%-2.1%) of the hazardous and harmful drinking respondents. The likelihood of having ever received advice/support was positively associated with being older (odds ratio (OR)=1.03 per year, 95%CI=1.01-1.04), a current or former (versus never) smoker (OR=2.36, 95%CI=1.46-3.80; OR=2.17, 95%CI=1.23-3.81), and with increasing alcohol consumption (OR=1.76 per score, 95%CI=1.59-1.95). One in two harmful drinking respondents (AUDIT-C score 10-12) reported appropriate advice/support. The likelihood was negatively associated with being female (e.g., OR=0.32, 95%CI=0.21-0.48), having a medium and high (versus low) education, and with increasing household income.Conclusions A small proportion of people drinking at hazardous and harmful levels in Germany report having ever received brief GP advice on, or support with, reducing alcohol consumption. The implementation of appropriate advice or support seems to be strongly linked to specific sociodemographic characteristics, tobacco smoking, and the alcohol consumption level.Strengths and limitations of this studyThe principal strength of this study is the large, nationally representative population sample.The cross-sectional study design and temporality issues with our measures (alcohol consumption was measured with reference to the present and the outcome as “ever receipt of GP advice or support”) limited our ability to explore causal relationships.The outcome measure had a complex, not entirely hierarchical structure, which may have led to respondents being unsure of which response option to select.Data were collected during the COVID-19 pandemic, during which alcohol consumption in Germany seemed to have changed. It is unclear how this might have influenced GPs’ behaviour.Due to the socially loaded topic, respondents may not have answered truthfully or repressed a previous conversation with their GP on their alcohol consumption. We did not assess the GPs’ view on the topic.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://osf.io/3fe87/ Funding StatementFrom 2016 to 2019 (waves 1-18), the DEBRA study was supported by the Ministry of Innovation, Science and Research of the German State of North Rhine–Westphalia (MIWF) in the context of the ″NRW Rueckkehrprogramm″ (the North Rhine–Westphalian postdoc return program). Since 2019 (wave 19 onwards), the study has been supported by the German Federal Ministry of Health.CG is funded by Cancer Research UK and the National Institute for Health Research. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol has been peer-reviewed and approved by the ethics committee of Heinrich-Heine-University Duesseldorf, Germany (HHU 5386/R).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data underlying this study are third-party data and are available to researchers on reasonable request from the corresponding author (sabrina.kastaun{at}med.uni-duesseldorf.de). All proposals requesting data access will need to specify how it is planned to use the data, and all proposals will need approval of the DEBRA study team before data release.